.
MergerLinks Header Logo

Announced

Completed

Fidelity Management & Research Company led a $110m Series B round in T-knife Therapeutics.

Financials

Edit Data
Transaction Value£79m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Friendly

Venture Capital

Acquisition

Single Bidder

Completed

Minority

Biotechnology

biotechnology

Germany

Private Equity

Cross Border

Private

Synopsis

Edit

Fidelity Management & Research Company led a $110m Series B round in T-knife Therapeutics, a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, with participation from LSP, Qatar Investment Authority, Casdin Capital, Sixty Degree Capital, CaaS Capital, RA Capital Management, Versant Ventures and Andera Partners. The company plans to use proceeds from the financing to expand its scientific team, increase manufacturing capacity and advance its pipeline of T-cell receptor engineered T cell therapies.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US